Related Experiment Video
Updated: Jul 2, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.6K
Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel
Andrea Mormone1, Giovanni Tortorella1, Francesca Esposito1
1Department of Advanced Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, 80131 Naples, Italy.
Biomedicines
|February 24, 2024
Summary
High cholesterol, especially elevated low-density lipoprotein cholesterol (LDL-C), increases cardiovascular risk. Newer non-statin therapies offer effective alternatives for managing hypercholesterolemia and reducing disease risks.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Diseases
Background:
- Hypercholesterolemia, characterized by elevated cholesterol levels, is a primary driver of atherosclerotic plaque formation.
- High low-density lipoprotein cholesterol (LDL-C) significantly elevates risks for cardiovascular, cerebrovascular, and peripheral arterial diseases.
- Effective management of hypercholesterolemia is critical for reducing cardiovascular morbidity and mortality.
Purpose of the Study:
- To review the latest therapeutic strategies for managing hypercholesterolemia.
- To elucidate the mechanisms of action for novel non-statin cholesterol-lowering agents.
- To evaluate the therapeutic benefits and cost-effectiveness of emerging hypercholesterolemia treatments.
Main Methods:
- Literature review of recent clinical trials and pharmacological studies.
- Analysis of drug mechanisms targeting cholesterol synthesis and metabolism.
- Comparative assessment of efficacy, safety, and cost-benefit profiles of different therapeutic classes.
Main Results:
- Statins, inhibiting HMG-CoA reductase, have been a cornerstone therapy.
- Emerging non-statin agents offer alternative pathways for LDL-C reduction.
- Newer therapies demonstrate favorable cost-benefit ratios and provide viable treatment options.
Conclusions:
- Controlling LDL-C is a key modifiable risk factor for cardiovascular disease prevention.
- Non-statin therapies represent significant advancements in hypercholesterolemia management.
- Latest therapeutic options expand treatment paradigms, improving patient outcomes and adherence.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
513
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
513
01:29Cholesterol: Significance and Regulation
544
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
544
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166